Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: SELL (auto-tracking)
-1.42% $3.46
America/New_York / 18 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 585.06 mill |
EPS: | -2.09 |
P/E: | -1.660 |
Earnings Date: | May 01, 2024 |
SharesOutstanding: | 169.09 mill |
Avg Daily Volume: | 2.36 mill |
RATING 2024-04-18 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Sell | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Buy | |
P/E: | Neutral | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -1.660 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.28x |
Company: PE -1.660 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$-0.0772 (-102.23%) $-3.54 |
Date: 2024-04-18 |
Expected Trading Range (DAY) |
---|
$ 3.11 - 3.81 ( +/- 10.09%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-14 | Chang David D | Sell | 53 393 | Common Stock |
2024-01-30 | Parker Geoffrey M. | Buy | 190 | Common Stock |
2024-01-25 | Moore Timothy L. | Buy | 341 515 | Stock Option (Right to buy) |
2024-01-25 | Moore Timothy L. | Buy | 96 600 | Common Stock |
2024-01-25 | Douglas Earl Martin | Buy | 41 800 | Common Stock |
INSIDER POWER |
---|
93.19 |
Last 94 transactions |
Buy: 32 956 491 | Sell: 32 061 810 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $3.46 (-1.42% ) |
Volume | 1.246 mill |
Avg. Vol. | 2.36 mill |
% of Avg. Vol | 52.80 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $4.33 | N/A | Active |
---|
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.